JP2016517404A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016517404A5 JP2016517404A5 JP2015562520A JP2015562520A JP2016517404A5 JP 2016517404 A5 JP2016517404 A5 JP 2016517404A5 JP 2015562520 A JP2015562520 A JP 2015562520A JP 2015562520 A JP2015562520 A JP 2015562520A JP 2016517404 A5 JP2016517404 A5 JP 2016517404A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- insulin
- transcription factor
- pancreatic
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361787054P | 2013-03-15 | 2013-03-15 | |
| US61/787,054 | 2013-03-15 | ||
| PCT/IB2014/059779 WO2014141165A1 (en) | 2013-03-15 | 2014-03-14 | Use of insulin signaling antagonists, optionally in combination of transfection of non-beta cells, for inducing insulin production |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016517404A JP2016517404A (ja) | 2016-06-16 |
| JP2016517404A5 true JP2016517404A5 (enExample) | 2017-04-13 |
Family
ID=50440717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562520A Withdrawn JP2016517404A (ja) | 2013-03-15 | 2014-03-14 | インスリン産生の誘導方法およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20160067212A1 (enExample) |
| EP (1) | EP2968472A1 (enExample) |
| JP (1) | JP2016517404A (enExample) |
| CA (1) | CA2904198A1 (enExample) |
| WO (1) | WO2014141165A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0906473A8 (pt) | 2008-01-04 | 2016-02-10 | Intellikine Inc | Certas entidades químicas, composições e métodos |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| EP3238722B1 (en) | 2011-01-10 | 2019-03-13 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| RU2702908C2 (ru) | 2012-11-01 | 2019-10-14 | Инфинити Фармасьютикалз, Инк. | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| AU2015349890B2 (en) | 2014-11-21 | 2018-08-30 | Merck Sharp & Dohme Llc | Insulin receptor partial agonists |
| US11058775B2 (en) | 2016-04-26 | 2021-07-13 | Merck Sharp & Dohme Corp. | Insulin dimer-incretin conjugates |
| WO2017205191A1 (en) | 2016-05-24 | 2017-11-30 | Merck Sharp & Dohme Corp. | Insulin receptor partial agonists and glp-1 analogues |
| US10689430B2 (en) | 2016-05-25 | 2020-06-23 | Merck Sharp & Dohme Corp. | Insulin receptor partial agonists |
| EP3474856B1 (en) | 2016-06-24 | 2022-09-14 | Infinity Pharmaceuticals, Inc. | Combination therapies |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6413773B1 (en) * | 1998-06-01 | 2002-07-02 | The Regents Of The University Of California | Phosphatidylinositol 3-kinase inhibitors as stimulators of endocrine differentiation |
| US20040132679A1 (en) * | 2002-09-03 | 2004-07-08 | Baylor College Of Medicine | Induction of pancreatic islet formation |
| EP1624898A1 (en) * | 2003-05-12 | 2006-02-15 | Sarah Ferber | Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues |
| EP2575459A4 (en) | 2010-06-04 | 2014-03-12 | Oncothyreon Inc | CANCER TREATMENT WITH WORDMAN ANALOGA |
| CN104039357A (zh) * | 2011-06-10 | 2014-09-10 | 哈佛学院校长同事会 | 胰腺β-细胞增殖的调节 |
-
2014
- 2014-03-14 CA CA2904198A patent/CA2904198A1/en not_active Abandoned
- 2014-03-14 US US14/774,166 patent/US20160067212A1/en not_active Abandoned
- 2014-03-14 WO PCT/IB2014/059779 patent/WO2014141165A1/en not_active Ceased
- 2014-03-14 EP EP14715686.3A patent/EP2968472A1/en not_active Withdrawn
- 2014-03-14 JP JP2015562520A patent/JP2016517404A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ai et al. | MicroRNA-195 protects against dementia induced by chronic brain hypoperfusion via its anti-amyloidogenic effect in rats | |
| Reinhardt et al. | Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression | |
| Shi et al. | Increased miR‐195 aggravates neuropathic pain by inhibiting autophagy following peripheral nerve injury | |
| She et al. | 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors | |
| Andreassen et al. | Identification of differentially expressed Atlantic salmon miRNAs responding to salmonid alphavirus (SAV) infection | |
| Kaalund et al. | Aberrant expression of miR‐218 and miR‐204 in human mesial temporal lobe epilepsy and hippocampal sclerosis—Convergence on axonal guidance | |
| Schäffner et al. | FoxO function is essential for maintenance of autophagic flux and neuronal morphogenesis in adult neurogenesis | |
| Zheng et al. | μ-Opioid receptor agonists differentially regulate the expression of miR-190 and NeuroD | |
| López-Pelaéz et al. | Cot/tpl2-MKK1/2-Erk1/2 controls mTORC1-mediated mRNA translation in Toll-like receptor–activated macrophages | |
| Shen et al. | RanBP2/Nup358 enhances miRNA activity by sumoylating Argonautes | |
| US9238815B2 (en) | Compositions and methods for inhibiting human host factors required for influenza virus replication | |
| Wu et al. | MicroRNA-181a protects against pericyte apoptosis via directly targeting FOXO1: implication for ameliorated cognitive deficits in APP/PS1 mice | |
| Shi et al. | Coxsackievirus A16 elicits incomplete autophagy involving the mTOR and ERK pathways | |
| Li et al. | LncRNA H19 promotes inflammatory response induced by cerebral ischemia–reperfusion injury through regulating the miR-138-5p–p65 axis | |
| Liu et al. | The critical role of myostatin in differentiation of sheep myoblasts | |
| Liu et al. | EPZ015666, a selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an antitumour effect in retinoblastoma | |
| AU2019205944A1 (en) | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition | |
| Xu et al. | Myricetin induces M2 macrophage polarization to alleviate renal tubulointerstitial fibrosis in diabetic nephropathy via PI3K/Akt pathway | |
| Zhang et al. | Enterovirus A71 oncolysis of malignant gliomas | |
| Bai et al. | Deficiency of miR-29b2/c leads to accelerated aging and neuroprotection in MPTP-induced Parkinson’s disease mice | |
| CY1120057T1 (el) | Μοριακη γενετικη προσεγγιση της θεραπειας και διαγνωσης της εξαρτησης απο το αλκοολ και τα ναρκωτικα | |
| Wojcieszak et al. | Induction of immediate early genes expression in the mouse striatum following acute administration of synthetic cathinones | |
| Duarte et al. | Rotavirus infection alters splicing of the stress-related transcription factor XBP1 | |
| Huang et al. | MiR‐29b expression is associated with a dexmedetomidine‐mediated protective effect against oxygen‐glucose deprivation‐induced injury to SK‐N‐SH cells in vitro | |
| Li et al. | Retracted: MicroR‐9‐5p suppresses EV 71 replication through targeting NF κB of the RIG‐I‐mediated innate immune response |